Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Medtronic (MDT) and Merck & Company (MRK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neogen (NEOG – Research Report), Medtronic (MDT – Research Report) and Merck & Company (MRK – Research Report).

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Neogen (NEOG)

Guggenheim analyst Subbu Nambi reiterated a Buy rating on Neogen yesterday and set a price target of $8.00. The company’s shares closed last Thursday at $6.78.

According to TipRanks.com, Nambi is a 4-star analyst with an average return of 17.9% and a 74.6% success rate. Nambi covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Adaptive Biotechnologies, and Nautilus Biotechnolgy. ;'>

Currently, the analyst consensus on Neogen is a Hold with an average price target of $7.25.

See the top stocks recommended by analysts >>

Medtronic (MDT)

Piper Sandler analyst Matthew O’Brien maintained a Hold rating on Medtronic today and set a price target of $90.00. The company’s shares closed last Thursday at $96.50.

According to TipRanks.com, O’Brien ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.2% and a 39.9% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Shoulder Innovations, Inc., and Orchestra BioMed Holdings. ;'>

Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $101.25, a 3.1% upside from current levels. In a report issued on October 8, Stifel Nicolaus also maintained a Hold rating on the stock with a $105.00 price target.

Merck & Company (MRK)

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Merck & Company today and set a price target of $90.00. The company’s shares closed last Thursday at $87.50, close to its 52-week low of $81.04.

According to TipRanks.com, Bansal is a 4-star analyst with an average return of 9.2% and a 58.7% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Milestone Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $96.09, a 10.5% upside from current levels. In a report issued on September 25, Bernstein also maintained a Hold rating on the stock.

Read More on NEOG:

Disclaimer & DisclosureReport an Issue

• Neogen Reports Q1 2026 Earnings and Strategic Changes
• Neogen’s Earnings Call: Mixed Sentiments and Strategic Focus
• Midday Fly By: Delta beats, PepsiCo names new CFO
• Neogen’s Mixed Financial Signals: Hold Rating Amid Promising Results and Strategic Concerns
• Neogen backs FY26 revenue view $820M-$840M, consensus $819.1M